Top 5 Stocks to Buy Now
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free OCSAW Stock Alerts

Oculis (OCSAW) Competitors

Oculis logo
$4.22 0.00 (0.00%)
As of 06/26/2026 03:38 PM Eastern
Compare

OCSAW vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you buy Oculis stock or one of its competitors? MarketBeat compares Oculis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oculis include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). These companies are all part of the "biotechnology" industry.

How does Oculis compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Oculis (NASDAQ:OCSAW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Oculis had 3 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 4 mentions for Oculis and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Oculis' score of 0.66 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Oculis Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Oculis N/A N/A N/A

Summary

60 Degrees Pharmaceuticals beats Oculis on 2 of the 3 factors compared between the two stocks.

How does Oculis compare to Alpha Tau Medical?

Oculis (NASDAQ:OCSAW) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Oculis had 1 more articles in the media than Alpha Tau Medical. MarketBeat recorded 4 mentions for Oculis and 3 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.96 beat Oculis' score of 0.66 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alpha Tau Medical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
OculisN/A N/A N/A
Alpha Tau Medical N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OculisN/AN/AN/AN/AN/A
Alpha Tau MedicalN/AN/AN/AN/AN/A

Summary

Oculis and Alpha Tau Medical tied by winning 1 of the 2 factors compared between the two stocks.

How does Oculis compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Oculis (NASDAQ:OCSAW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

In the previous week, Oculis had 2 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Apollomics. Apollomics' average media sentiment score of 0.94 beat Oculis' score of 0.66 indicating that Apollomics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apollomics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oculis
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Oculis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Summary

Apollomics beats Oculis on 2 of the 3 factors compared between the two stocks.

How does Oculis compare to BioVie?

BioVie (NASDAQ:BIVIW) and Oculis (NASDAQ:OCSAW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Oculis had 2 more articles in the media than BioVie. MarketBeat recorded 4 mentions for Oculis and 2 mentions for BioVie. BioVie's average media sentiment score of 0.94 beat Oculis' score of 0.66 indicating that BioVie is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioVie
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oculis
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Oculis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

Summary

BioVie and Oculis tied by winning 1 of the 2 factors compared between the two stocks.

How does Oculis compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIOW) and Oculis (NASDAQ:OCSAW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Cardio DiagnosticsN/A N/A N/A
Oculis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$16.57KN/AN/AN/AN/A
OculisN/AN/AN/AN/AN/A

In the previous week, Oculis had 2 more articles in the media than Cardio Diagnostics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.43 beat Oculis' score of 0.66 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Cardio Diagnostics Positive
Oculis Positive

Summary

Cardio Diagnostics beats Oculis on 2 of the 3 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCSAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCSAW vs. The Competition

Export
MetricOculisBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$496.87M$6.70B$12.22B
Dividend YieldN/A3.86%2.67%6.13%
P/E RatioN/A3.1825.7624.17
Price / SalesN/A7,182.14559.68101.60
Price / CashN/A13.1346.9954.37
Price / BookN/A88.5410.776.35
Net IncomeN/A-$96.07M$3.57B$337.63M
7 Day Performance-5.80%1.93%2.15%0.06%
1 Month Performance-78.54%0.96%1.06%-0.15%
1 Year Performance-52.69%70.54%34.16%27.55%

Oculis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCSAW
Oculis
N/A$4.22
flat		N/A-52.7%$0.00N/AN/A32
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
-5.1%		N/AN/A$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$1.93
-2.3%		N/A+740.7%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.01
-1.6%		N/A-68.7%$0.00$8.50MN/A59
BIVIW
BioVie
N/A$0.33
+5.1%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OCSAW) was last updated on 6/27/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel